Companies SI-Bone, Inc.
SI-Bone (SIBN): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me SI-Bone, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers67th pct.Of 18 peer CEOs
CEO pay, last three years
- $3,713,871FY2023
- $7,087,404FY2024
- $7,453,235FY2025
CEO total pay was $7,453,235 in fiscal 2025, up from $7,087,404 in fiscal 2024.
FY2025: salary $685,000 · bonus $0 · stock awards $6,038,710 · option awards $0
Executives and directors
Frequently asked questions
Who was the highest-paid executive at SI-Bone, Inc. in fiscal 2025?
As disclosed, Laura Francis (Chief Executive Officer) was the highest-paid executive at SI-Bone, Inc. in fiscal 2025, with total compensation of $7,453,235.
How does SI-Bone, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Laura Francis's total compensation ranked at the 67th percentile of SI-Bone, Inc.'s disclosed peer group.
What is SI-Bone, Inc.'s CEO-to-median employee pay ratio?
As disclosed, SI-Bone, Inc.'s CEO-to-median employee pay ratio was 41:1.
How did shareholders vote on SI-Bone, Inc.'s executive compensation?
As disclosed, 92.8% of shareholders supported SI-Bone, Inc.'s executive compensation in the latest say-on-pay vote.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Laura Francis | $685,000 | $0 | $6,038,710 | $0 | $729,525 | $0 | $0 | $7,453,235 |
| Chief Executive Officer | ||||||||
| Anshul Maheshwari | 496,668 | 0 | 1,977,240 | 0 | 317,371 | 0 | 0 | 2,791,279 |
| Chief Operating Officer & Chief Financial Officer | ||||||||
| Anthony Recupero | 500,580 | 0 | 1,544,730 | 0 | 399,838 | 0 | 0 | 2,445,148 |
| Former President, Commercial Operations | ||||||||
| Michael Pisetsky | 493,407 | 0 | 1,606,500 | 0 | 262,739 | 0 | 0 | 2,362,646 |
| Chief Business & Legal Affairs Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Laura Francis | $7,453,235 | $7,087,404 | $3,713,871 | ↑ +365,831 |
| Anshul Maheshwari | 2,791,279 | 2,470,353 | 1,860,681 | ↑ +320,926 |
| Anthony Recupero | 2,445,148 | 2,563,537 | 2,057,098 | ↓ −118,389 |
| Michael Pisetsky | 2,362,646 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
We have designed our executive compensation program to reward our Named Executive Officers at a level consistent with our overall strategic and financial performance and to provide remuneration sufficient to attract, retain, and motivate them to exert their best efforts in the highly competitive environment in which we operate. We believe that competitive compensation packages consisting of a combination of base salaries, annual cash bonus opportunities, and long-term incentive opportunities in the form of equity awards that are earned over a multi-year period enable us to attract top talent, motivate successful short-term and long-term performance, satisfy our retention objectives, and align the compensation of our executive officers with our performance and long-term value creation for our stockholders.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia, Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Laura Francis | PSU | 2025-02-03 | — | 91,736 | — | 183,472 | $2,916,000 |
| Anthony Recupero | PSU | 2025-02-03 | — | 18,646 | — | 37,291 | 592,682 |
| Michael Pisetsky | RSU | 2025-02-03 | — | — | 58,174 | — | 990,121 |
| Anshul Maheshwari | PSU | 2025-02-03 | — | 23,866 | — | 47,732 | 758,625 |
| Michael Pisetsky | PSU | 2025-02-03 | — | 19,391 | — | 38,782 | 616,379 |
| Laura Francis | PSU | 2025-02-03 | — | 30,579 | — | 61,158 | 1,040,909 |
| Anshul Maheshwari | RSU | 2025-02-03 | — | — | 71,599 | — | 1,218,615 |
| Laura Francis | RSU | 2025-02-03 | — | — | 122,315 | — | 2,081,801 |
| Anthony Recupero | RSU | 2025-02-03 | — | — | 55,937 | — | 952,048 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Laura Francis | $2,081,801 | $3,956,909 | $0 | 65.5% |
| Anthony Recupero | 952,048 | 592,682 | 0 | 38.4% |
| Michael Pisetsky | 990,121 | 616,379 | 0 | 38.4% |
| Anshul Maheshwari | 1,218,615 | 758,625 | 0 | 38.4% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Michael Pisetsky | RSU | 323 | — | $6,370 |
| Anshul Maheshwari | RSU | 2,613 | — | 51,528 |
| Michael Pisetsky | RSU | 2,903 | — | 57,247 |
| Laura Francis | RSU | 3,992 | — | 78,722 |
| Anthony Recupero | RSU | 4,354 | — | 85,861 |
| Michael Pisetsky | RSU | 17,639 | — | 347,841 |
| Anshul Maheshwari | RSU | 17,962 | — | 354,211 |
| Anthony Recupero | RSU | 17,962 | — | 354,211 |
| Laura Francis | RSU | 21,954 | — | 432,933 |
| Michael Pisetsky | RSU | 22,953 | — | 452,633 |
| Anshul Maheshwari | PSU | 23,041 | — | 454,369 |
| Anthony Recupero | PSU | 23,041 | — | 454,369 |
| Michael Pisetsky | PSU | 25,068 | — | 494,341 |
| Michael Pisetsky | PSU | 25,546 | — | 503,767 |
| Anshul Maheshwari | RSU | 28,691 | — | 565,787 |
| Anthony Recupero | RSU | 28,691 | — | 565,787 |
| Anshul Maheshwari | PSU | 31,334 | — | 617,906 |
| Anthony Recupero | PSU | 31,334 | — | 617,906 |
| Anthony Recupero | PSU | 37,291 | — | 735,379 |
| Michael Pisetsky | PSU | 38,782 | — | 764,781 |
| Anthony Recupero | RSU | 45,449 | — | 896,254 |
| Michael Pisetsky | RSU | 47,266 | — | 932,086 |
| Anshul Maheshwari | PSU | 47,732 | — | 941,275 |
| Laura Francis | RSU | 56,617 | — | 1,116,487 |
| Anshul Maheshwari | RSU | 58,174 | — | 1,147,191 |
| Laura Francis | PSU | 84,484 | — | 1,666,024 |
| Laura Francis | RSU | 145,861 | — | 2,876,379 |
| Laura Francis | PSU | 183,472 | — | 3,618,068 |
| Laura Francis | PSU | 185,497 | — | 3,658,001 |
Director compensation
No director compensation table is on file for fiscal year 2025.
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $150,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | $3 |
Peer group, and who names SI-Bone as a peer
Companies that benchmark against SIBN
9 companies name SIBN as a compensation peer
- ANGIODYNAMICS INCANGOFY2026
- Axogen, Inc.AXGNFY2025
- KESTRA MEDICAL TECHNOLOGIES, LTD.KMTSFY2026
- Outset Medical, Inc.OMFY2025
- RxSight, Inc.RXSTFY2025
- Sight Sciences, Inc.SGHTFY2025
- SURMODICS INCSRDXFY2024
- SURMODICS INCSRMDFY2024
- TACTILE SYSTEMS TECHNOLOGY INCTCMDFY2025
Each company listed discloses SIBN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SIBN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
OFIX Orthofix Medical Inc.RXST RxSight, Inc.STAA STAAR Surgical CompanyKIDS OrthoPediatrics Corp.SGHT Sight Sciences, Inc.AXGN Axogen, Inc.ATEC Alphatec Holdings, Inc.AORT Artivion, Inc.CERS Cerus CorporationLMAT LeMaitre Vascular, Inc.PRCT PROCEPT BioRobotics CorporationTCMD Tactile Systems Technology, Inc.TMCI Treace Medical Concepts, Inc.VCEL Vericel CorporationFNA Paragon 28, Inc.LUNG Pulmonx CorporationSILK Silk Road Medical, Inc.ZYXI Zynex, Inc.
Peer reciprocity
The companies SI-Bone, Inc. names as compensation peers that name it back in their own disclosed peer groups.
RxSight, Inc. (RXST)97Sight Sciences, Inc. (SGHT)98Axogen, Inc. (AXGN)99Tactile Systems Technology, Inc. (TCMD)100Paragon 28, Inc. (FNA)101
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Procept BioRobotics Corporation | 2025 | Larry Wood | $304,830 | $7,217,251 | $7,226,599 | $243,864 | $16,783,853 |
| 2 | Silk Road Medical, Inc. | 2023 | Chas McKhann | 105,871 | 13,123,059 | 0 | 93,275 | 13,423,834 |
| 3 | Vericel Corporation | 2025 | Dominick Colangelo | 860,000 | 3,964,630 | 5,456,287 | 860,000 | 11,156,368 |
| 4 | Alphatec Holdings, Inc. | 2025 | Patrick Miles | 762,000 | 8,859,650 | 0 | 600,000 | 10,260,507 |
| 5 | Axogen, Inc. | 2025 | Michael Dale | 775,865 | 7,342,895 | 0 | 906,133 | 9,047,454 |
| 6 | Staar Surgical Company | 2025 | Stephen Farrell | 580,000 | 6,836,000 | 0 | 0 | 7,522,385 |
| 7 | SI-Bone, Inc. | 2025 | Laura Francis | 685,000 | 6,038,710 | 0 | 729,525 | 7,453,235 |
| 8 | Orthofix Medical Inc. | 2025 | Massimo Calafiore | 848,322 | 4,499,988 | 1,500,009 | 445,579 | 7,310,039 |
| 9 | Artivion, Inc. | 2025 | J. Patrick Mackin | 835,145 | 5,006,990 | 0 | 991,368 | 6,883,108 |
| 10 | Treace Medical Concepts, Inc. | 2025 | John Treace | 755,353 | 4,635,000 | 0 | 0 | 5,405,190 |
| 11 | RxSight, Inc. | 2025 | Ron Kurtz | 630,625 | 0 | 3,816,530 | 202,935 | 4,650,661 |
| 12 | Cerus Corporation | 2025 | William Greenman | 793,750 | 2,242,585 | 0 | 756,000 | 3,794,657 |
| 13 | LeMaitre Vascular, Inc. | 2025 | George LeMaitre | 806,347 | 1,050,000 | 1,050,000 | 680,015 | 3,780,990 |
| 14 | Pulmonx Corporation | 2025 | Glendon French | 116,186 | 3,224,000 | 0 | 0 | 3,543,520 |
| 15 | Tactile Systems Technology, Inc. | 2025 | Sheri Dodd | 675,000 | 2,019,978 | 0 | 737,438 | 3,466,916 |
| 16 | OrthoPediatrics Corp. | 2025 | David Bailey | 550,000 | 2,445,200 | 0 | 322,281 | 3,331,481 |
| 17 | Paragon 28, Inc. | 2023 | Albert DaCosta | 700,769 | 1,832,495 | 0 | 667,400 | 3,232,420 |
| 18 | Sight Sciences, Inc. | 2025 | Paul Badawi | 659,000 | 1,000,000 | 0 | 334,607 | 2,005,608 |
| 19 | Zynex, Inc. | 2024 | Thomas Sandgaard | 700,000 | 112,458 | 0 | 170,625 | 991,810 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| SI-Bone, Inc. | 106.5% | RSU 50 · PSU 50 | Yes — Relative TSR | Compensia, Inc. |
| Alphatec Holdings, Inc. | 157% | PSU 50 · RSU 50 | No | Compensia |
| Artivion, Inc. | 118.7% | PSU 50 · RSU 50 | No | Willis Towers Watson |
| Axogen, Inc. | 116.79% | PSU 50 · RSU 50 | No | Aon |
| Cerus Corporation | 126% | not disclosed | No | Alpine |
| LeMaitre Vascular, Inc. | not disclosed | Option 50 · RSU 25 · PSU 25 | No | not disclosed |
| Orthofix Medical Inc. | 47.7% | PSU 50 · Option 25 · RSU 25 | No | Meridian |
| OrthoPediatrics Corp. | 78.2% | RSU 100 | not disclosed | NFP Compensation Consulting |
| Paragon 28, Inc. | 94% | RSU 100 | not disclosed | Compensia, Inc. |
| Procept BioRobotics Corporation | 80% | RSU 50 · PSU 25 · Options 25 | Yes — Relative TSR | Alpine |
| Pulmonx Corporation | not disclosed | RSU 75 · PRSU 25 | not disclosed | Frederic W. Cook & Co., Inc. |
| RxSight, Inc. | 32.18% | Option 100 | not disclosed | Aon |
| Sight Sciences, Inc. | not disclosed | RSU 100 | not disclosed | Compensia, Inc. |
| Silk Road Medical, Inc. | not disclosed | PSU 50 · RSU 50 | Yes — Total Stockholder Return (TSR) relative to peer group | Compensia, Inc. |
| Staar Surgical Company | 135% | RSU 50 · PSU 50 | No | Semler Brossy |
| Tactile Systems Technology, Inc. | 115% | PSU 50 · RSU 50 | No | Aon Consulting, Inc. |
| Treace Medical Concepts, Inc. | not disclosed | RSU 50 · PSU 50 | No | Compensia, Inc. |
| Vericel Corporation | 100% | Options 58 · RSU 42 | not disclosed | FW Cook |
| Zynex, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-04-06 | 33,265,992 | 2,579,849 | 17,463 | 92.8% | Passed |
| 2025 | 2025-06-05 | 35,588,516 | 616,661 | 3,625 | 98.3% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-04-06 | 92.8%a |
| 2025 | 2025-06-05 | 98.3%b |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 41 : 1 |
|---|---|
| CEO total compensation | $7,453,235 |
| Median employee compensation | $181,059 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jeffrey W. Dunn | Director | 2026-05-04 | D | 337 | $13 | $4,432 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-05-18 | D | 1,973 | 15 | 28,745 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-05-18 | D | 2,236 | 15 | 32,813 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-05-18 | D | 3,652 | 15 | 53,867 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-05-18 | D | 3,893 | 15 | 57,403 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Financial Officer | 2026-05-18 | D | 2,477 | 15 | 36,445 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-05-18 | D | 1,872 | 15 | 27,392 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-05-18 | D | 1,854 | 15 | 27,134 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Financial Officer | 2026-05-18 | D | 2,189 | 15 | 32,079 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-05-18 | D | 3,203 | 15 | 47,172 | Common, open-market sale | Form 4 ↗ |
| Timothy E. Davis JR | Director | 2026-05-28 | D | 3,780 | 14 | 54,699 | Common, open-market sale | Form 4 ↗ |
| Timothy E. Davis JR | Director | 2026-05-28 | A | 12,064 | 4 | 52,116 | Common | Form 4 ↗ |
| Timothy E. Davis JR | Director | 2026-05-28 | D | 12,064 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy E. Davis JR | Director | 2026-05-29 | D | 3,500 | 14 | 49,488 | Common, open-market sale | Form 4 ↗ |
| Timothy E. Davis JR | Director | 2026-06-04 | A | 10,957 | 0 | 0 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-06-04 | A | 10,957 | 0 | 0 | Common | Form 4 ↗ |
| Thomas A. West | Director | 2026-06-04 | A | 10,957 | 0 | 0 | Common | Form 4 ↗ |
| Jeryl L. Hilleman | Director | 2026-06-04 | A | 10,957 | 0 | 0 | Common | Form 4 ↗ |
| John Gordon Freund | Director | 2026-06-04 | A | 10,957 | 0 | 0 | Common | Form 4 ↗ |
| Mika Nishimura | Director | 2026-06-04 | A | 10,957 | 0 | 0 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-06-05 | D | 3,575 | 15 | 54,505 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-07-02 | D | 1,799 | 17 | 30,042 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Financial Officer | 2026-07-02 | D | 1,757 | 17 | 29,521 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-07-02 | D | 1,301 | 17 | 21,760 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Financial Officer | 2026-07-02 | D | 1,560 | 17 | 26,106 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-07-02 | D | 34 | 17 | 573 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-08-03 | D | 20,000 | 18 | 369,214 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-08-03 | A | 20,000 | 5 | 93,600 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-08-03 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laura Francis | Director | 2026-08-17 | D | 3,892 | 19 | 72,616 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-08-17 | D | 1,973 | 19 | 36,755 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Financial Officer | 2026-08-17 | D | 2,476 | 19 | 46,251 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-08-17 | D | 1,854 | 19 | 34,513 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-08-17 | D | 1,871 | 19 | 34,898 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-08-17 | D | 3,652 | 19 | 68,144 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-08-17 | D | 3,203 | 19 | 59,778 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Financial Officer | 2026-08-17 | D | 2,189 | 19 | 40,764 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-08-17 | D | 2,236 | 19 | 41,772 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Op & Financial Officer | 2026-08-19 | D | 5,747 | 20 | 112,354 | Common | Form 4 ↗ |
| Laura Francis | Director | 2026-08-20 | D | 51,884 | 19 | 1,009,663 | Common | Form 4 ↗ |
| Anshul Maheshwari | Chief Op & Financial Officer | 2026-08-21 | D | 11,228 | 20 | 224,785 | Common | Form 4 ↗ |
| Laura Francis | Director | 2026-08-21 | D | 3,923 | 20 | 78,538 | Common | Form 4 ↗ |
| Laura Francis | Director | 2026-08-24 | D | 25,972 | 20 | 522,596 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-09-01 | A | 1,367 | 5 | 6,398 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-09-01 | D | 18,633 | 19 | 352,313 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-09-01 | D | 18,633 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-01 | — | 1,367 | — | — | 1 insider, 1 accrual row | ||
| Jeffrey W. Dunn | Director | 2026-09-01 | A | 18,633 | 5 | 87,202 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-09-01 | D | 1,367 | 19 | 25,847 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-10-01 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-10-01 | D | 20,000 | 18 | 369,400 | Common, open-market sale | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-10-01 | A | 20,000 | 5 | 93,600 | Common | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-10-02 | D | 1,799 | 18 | 32,637 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-10-02 | D | 1,300 | 18 | 23,664 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Op & Financial Officer | 2026-10-02 | D | 1,758 | 18 | 31,984 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Op & Financial Officer | 2026-10-02 | D | 1,560 | 18 | 28,341 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-10-02 | D | 34 | 18 | 617 | Common | Form 4 ↗ |
| Anshul Maheshwari | Chief Op & Financial Officer | 2026-10-05 | D | 1,731 | 20 | 33,755 | Common | Form 4 ↗ |
| Laura Francis | Director | 2026-10-12 | D | 38,006 | 20 | 762,013 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 59 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jeffrey W. Dunn | Director | 2026-05-04 | D | 337 | $13 | $4,432 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-05-18 | D | 1,973 | 15 | 28,745 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-05-18 | D | 2,236 | 15 | 32,813 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-05-18 | D | 3,652 | 15 | 53,867 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-05-18 | D | 3,893 | 15 | 57,403 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Financial Officer | 2026-05-18 | D | 2,477 | 15 | 36,445 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-05-18 | D | 1,872 | 15 | 27,392 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-05-18 | D | 1,854 | 15 | 27,134 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Financial Officer | 2026-05-18 | D | 2,189 | 15 | 32,079 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-05-18 | D | 3,203 | 15 | 47,172 | Common, open-market sale | Form 4 ↗ |
| Timothy E. Davis JR | Director | 2026-05-28 | D | 3,780 | 14 | 54,699 | Common, open-market sale | Form 4 ↗ |
| Timothy E. Davis JR | Director | 2026-05-28 | A | 12,064 | 4 | 52,116 | Common | Form 4 ↗ |
| Timothy E. Davis JR | Director | 2026-05-28 | D | 12,064 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy E. Davis JR | Director | 2026-05-29 | D | 3,500 | 14 | 49,488 | Common, open-market sale | Form 4 ↗ |
| Timothy E. Davis JR | Director | 2026-06-04 | A | 10,957 | 0 | 0 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-06-04 | A | 10,957 | 0 | 0 | Common | Form 4 ↗ |
| Thomas A. West | Director | 2026-06-04 | A | 10,957 | 0 | 0 | Common | Form 4 ↗ |
| Jeryl L. Hilleman | Director | 2026-06-04 | A | 10,957 | 0 | 0 | Common | Form 4 ↗ |
| John Gordon Freund | Director | 2026-06-04 | A | 10,957 | 0 | 0 | Common | Form 4 ↗ |
| Mika Nishimura | Director | 2026-06-04 | A | 10,957 | 0 | 0 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-06-05 | D | 3,575 | 15 | 54,505 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-07-02 | D | 1,799 | 17 | 30,042 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Financial Officer | 2026-07-02 | D | 1,757 | 17 | 29,521 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-07-02 | D | 1,301 | 17 | 21,760 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Financial Officer | 2026-07-02 | D | 1,560 | 17 | 26,106 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-07-02 | D | 34 | 17 | 573 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-08-03 | D | 20,000 | 18 | 369,214 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-08-03 | A | 20,000 | 5 | 93,600 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-08-03 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laura Francis | Director | 2026-08-17 | D | 3,892 | 19 | 72,616 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-08-17 | D | 1,973 | 19 | 36,755 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Financial Officer | 2026-08-17 | D | 2,476 | 19 | 46,251 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-08-17 | D | 1,854 | 19 | 34,513 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-08-17 | D | 1,871 | 19 | 34,898 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-08-17 | D | 3,652 | 19 | 68,144 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-08-17 | D | 3,203 | 19 | 59,778 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Financial Officer | 2026-08-17 | D | 2,189 | 19 | 40,764 | Common, open-market sale | Form 4 ↗ |
| Laura Francis | Director | 2026-08-17 | D | 2,236 | 19 | 41,772 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Op & Financial Officer | 2026-08-19 | D | 5,747 | 20 | 112,354 | Common | Form 4 ↗ |
| Laura Francis | Director | 2026-08-20 | D | 51,884 | 19 | 1,009,663 | Common | Form 4 ↗ |
| Anshul Maheshwari | Chief Op & Financial Officer | 2026-08-21 | D | 11,228 | 20 | 224,785 | Common | Form 4 ↗ |
| Laura Francis | Director | 2026-08-21 | D | 3,923 | 20 | 78,538 | Common | Form 4 ↗ |
| Laura Francis | Director | 2026-08-24 | D | 25,972 | 20 | 522,596 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-09-01 | A | 1,367 | 5 | 6,398 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-09-01 | D | 18,633 | 19 | 352,313 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-09-01 | D | 18,633 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-09-01 | D | 1,367 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-09-01 | A | 18,633 | 5 | 87,202 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-09-01 | D | 1,367 | 19 | 25,847 | Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-10-01 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-10-01 | D | 20,000 | 18 | 369,400 | Common, open-market sale | Form 4 ↗ |
| Jeffrey W. Dunn | Director | 2026-10-01 | A | 20,000 | 5 | 93,600 | Common | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-10-02 | D | 1,799 | 18 | 32,637 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-10-02 | D | 1,300 | 18 | 23,664 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Op & Financial Officer | 2026-10-02 | D | 1,758 | 18 | 31,984 | Common, open-market sale | Form 4 ↗ |
| Anshul Maheshwari | Chief Op & Financial Officer | 2026-10-02 | D | 1,560 | 18 | 28,341 | Common, open-market sale | Form 4 ↗ |
| Michael Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 2026-10-02 | D | 34 | 18 | 617 | Common | Form 4 ↗ |
| Anshul Maheshwari | Chief Op & Financial Officer | 2026-10-05 | D | 1,731 | 20 | 33,755 | Common | Form 4 ↗ |
| Laura Francis | Director | 2026-10-12 | D | 38,006 | 20 | 762,013 | Common | Form 4 ↗ |
Sources (101 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Laura Francis. DEF 14A, filed 2026-04-21. Section “Executive Compensation”. As printed: 7,453,235. View filing ↗
- Section 01, Anshul Maheshwari. DEF 14A, filed 2026-04-21. Section “Executive Compensation”. As printed: 2,791,279. View filing ↗
- Section 01, Anthony Recupero. DEF 14A, filed 2026-04-21. Section “Executive Compensation”. As printed: 2,445,148. View filing ↗
- Section 01, Michael Pisetsky. DEF 14A, filed 2026-04-21. Section “Executive Compensation”. As printed: 2,362,646. View filing ↗
- Section 03, Laura Francis PSU. DEF 14A, filed 2026-04-21. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Anthony Recupero PSU. DEF 14A, filed 2026-04-21. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Pisetsky RSU. DEF 14A, filed 2026-04-21. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Anshul Maheshwari PSU. DEF 14A, filed 2026-04-21. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Pisetsky PSU. DEF 14A, filed 2026-04-21. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Laura Francis PSU. DEF 14A, filed 2026-04-21. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Anshul Maheshwari RSU. DEF 14A, filed 2026-04-21. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Laura Francis RSU. DEF 14A, filed 2026-04-21. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Anthony Recupero RSU. DEF 14A, filed 2026-04-21. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-21. Section “CEO Pay Ratio”. As printed: 41 : 1. View filing ↗
- Section 02, Jeffrey W. Dunn 2026-05-04. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Francis 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Francis 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Francis 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Francis 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Maheshwari 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Pisetsky 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Pisetsky 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Maheshwari 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Francis 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy E. Davis JR 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy E. Davis JR 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy E. Davis JR 2026-05-28. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy E. Davis JR 2026-05-29. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy E. Davis JR 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Dunn 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas A. West 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeryl L. Hilleman 2026-06-04. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Gordon Freund 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mika Nishimura 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Dunn 2026-06-05. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Pisetsky 2026-07-02. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Maheshwari 2026-07-02. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Pisetsky 2026-07-02. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Maheshwari 2026-07-02. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Pisetsky 2026-07-02. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Dunn 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Dunn 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Dunn 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Francis 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Francis 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Maheshwari 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Pisetsky 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Pisetsky 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Francis 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Francis 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Maheshwari 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Francis 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Maheshwari 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Francis 2026-08-20. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Maheshwari 2026-08-21. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Francis 2026-08-21. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Francis 2026-08-24. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Dunn 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Dunn 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Dunn 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Dunn 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Dunn 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Dunn 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Dunn 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Dunn 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey W. Dunn 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Pisetsky 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Pisetsky 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Maheshwari 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Maheshwari 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Pisetsky 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anshul Maheshwari 2026-10-05. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Francis 2026-10-12. Form 4, filed 2026-10-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-08. Item 5.07 · say-on-pay result. As reported: 92.8% (votes for as printed: 33,265,992). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-06. Item 5.07 · say-on-pay result. As reported: 98.3% (votes for as printed: 35,588,516). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Procept BioRobotics Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Procept BioRobotics Corporation's own proxy. As printed: 16,783,853. View filing ↗
- Silk Road Medical, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in Silk Road Medical, Inc.'s own proxy. As printed: 13,423,834. View filing ↗
- Vericel Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-19. CEO total compensation as printed in Vericel Corporation's own proxy. As printed: 11,156,368. View filing ↗
- Alphatec Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Alphatec Holdings, Inc.'s own proxy. As printed: 10,260,507. View filing ↗
- Axogen, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Axogen, Inc.'s own proxy. As printed: 9,047,454. View filing ↗
- Staar Surgical Company, Section 10b CEO total. DEF 14A, filed 2026-05-04. CEO total compensation as printed in Staar Surgical Company's own proxy. As printed: 7,522,385. View filing ↗
- SI-Bone, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in SI-Bone, Inc.'s own proxy. As printed: 7,453,235. View filing ↗
- Orthofix Medical Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Orthofix Medical Inc.'s own proxy. As printed: 7,310,039. View filing ↗
- Artivion, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Artivion, Inc.'s own proxy. As printed: 6,883,108. View filing ↗
- Treace Medical Concepts, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Treace Medical Concepts, Inc.'s own proxy. As printed: 5,405,190. View filing ↗
- RxSight, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in RxSight, Inc.'s own proxy. As printed: 4,650,661. View filing ↗
- Cerus Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Cerus Corporation's own proxy. As printed: 3,794,657. View filing ↗
- LeMaitre Vascular, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in LeMaitre Vascular, Inc.'s own proxy. As printed: 3,780,990. View filing ↗
- Pulmonx Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Pulmonx Corporation's own proxy. As printed: 3,543,520. View filing ↗
- Tactile Systems Technology, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Tactile Systems Technology, Inc.'s own proxy. As printed: 3,466,916. View filing ↗
- OrthoPediatrics Corp., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in OrthoPediatrics Corp.'s own proxy. As printed: 3,331,481. View filing ↗
- Paragon 28, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-05. CEO total compensation as printed in Paragon 28, Inc.'s own proxy. As printed: 3,232,420. View filing ↗
- Sight Sciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Sight Sciences, Inc.'s own proxy. As printed: 2,005,608. View filing ↗
- Zynex, Inc., Section 10b CEO total. DEF 14A, filed 2025-03-28. CEO total compensation as printed in Zynex, Inc.'s own proxy. As printed: 991,810. View filing ↗
- Section 10a, RxSight, Inc. reciprocity. DEF 14A. RxSight, Inc. names SI-Bone, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Sight Sciences, Inc. reciprocity. DEF 14A. Sight Sciences, Inc. names SI-Bone, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Axogen, Inc. reciprocity. DEF 14A. Axogen, Inc. names SI-Bone, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Tactile Systems Technology, Inc. reciprocity. DEF 14A. Tactile Systems Technology, Inc. names SI-Bone, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Paragon 28, Inc. reciprocity. DEF 14A. Paragon 28, Inc. names SI-Bone, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗